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Abstract
Resveratrol, a polyphenol present in grapes and red wine, has been studied due to its vast
pharmacological activity. It has been demonstrated that resveratrol inhibits production of
inflammatory mediators in different in vitro and in vivo models. Our group recently demonstrated
that resveratrol reduced the production of prostaglandin (PG) E2 and 8-isoprostane in rat activated
microglia. In a microglial-neuronal coculture, resveratrol reduced neuronal death induced by
activated microglia. However, less is known about its direct roles in neurons. In the present study,
we investigated the effects of resveratrol on interleukin (IL)-1β stimulated SK-N-SH cells.
Resveratrol (0.1-5 μM) did not reduce the expression of cyclooxygenase (COX)-2 and microsomal
PGE2 synthase-1 (mPGES-1), although it drastically reduced PGE2 and PGD2 content in IL-1β-
stimulated SK-N-SH cells. This effect was due, in part, to a reduction in COX enzymatic activity,
mainly COX-2, at lower doses of resveratrol. The production of 8-iso-PGF2α, a marker of cellular
free radical generation, was significantly reduced by resveratrol. The present work provides
evidence that resveratrol reduces the formation of prostaglandins in neuroblastoma cells by
reducing the enzymatic activity of inducible enzymes, such as COX-2, and not the transcription of
the PG synthases, as demonstrated elsewhere.
Findings
Neuroinflammation is an important component of neu-
rodegenerative diseases and different inflammatory medi-
ators contribute to the process of these disorders. The
prostanoids produced from the arachidonic acid (AA) cas-
cade seem to play important roles in these pathological
conditions. Among all prostanoids formed from the AA
cascade, prostaglandin (PG) E2 seems to play an impor-
tant role in the development of neuroinflammation. In
inflammatory conditions, the two enzymes that contrib-
ute the most to PGE2  production are cyclooxygenase
(COX)-2, which converts AA into PGG2 and PGH2, and
microsomal PGE2 synthase-1 (mPGES-1), which converts
PGH2 into PGE2 [1]. The involvement of PGE2, COX-2
and mPGES-1 in neurodegenerative diseases has been
extensively demonstrated [2,3].
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Resveratrol (trans-3, 5, 4'-trihydroxystilbene) is a
polyphenol found in many plants and in the red wine that
reveals several pharmacological actions, including anti-
inflammatory properties. Recent reports have evaluated
the potential protective role of resveratrol in neurodegen-
erative conditions. Resveratrol reduces the expression of
different inflammatory mediators involved in the progres-
sion of neuropathological conditions and it has been
shown to provide neuronal protection in different models
[4].
Although resveratrol has been shown to reduce the expres-
sion of different inflammatory mediators in some cells,
including glial cells, its influence in the production of
these molecules in neuronal cells has been less studied.
Therefore, in the present study, we investigated the effect
of resveratrol on the production of prostanoids induced
by IL-1β in SK-N-SH cells, a human neuroblastoma cell
line.
SK-N-SH cells were obtained from the American Type Cul-
ture Collection (HTB-11, Rockville, USA) and were grown
in MEM-Earle's medium (PAA, Cölbe, Germany), which
does not contain any anti-inflammatory substance.
Medium was supplemented with 5% fetal calf serum
(PAN, Aidenbach, Germany), 2 mM L-glutamine, 1 mM
sodium pyruvate, 40 units/ml penicillin/streptomycin (all
purchased from PAA Laboratories, Cölbe, Germany),
0.4% MEM vitamins and 0.4% MEM nonessential amino
acids (both purchased from Invitrogen GmbH, Karlsruhe,
Germany). Confluent monolayers were passaged rou-
tinely by trypsinization. Cultures were grown at 37°C in
5% CO2 until 80% confluence, and the medium was
changed the day before treatment.
To investigate the effect of resveratrol on the production
of inflammatory mediators in neuronal cells, SK-N-SH
neuronal cells were pre-incubated with different concen-
trations (0.001-5 μM) of resveratrol (Sigma-Aldrich,
Taufkirchen, Germany) for 30 minutes followed by stim-
ulation with IL-1β (10 U/ml) for 24 h. In control experi-
ments, cells were pre-incubated for 30 min with the
following COX inhibitors: SC-560 (5-(4-chlorophenyl)-1-
(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole)
(Cayman Chemical Co., Ann Arbor, Michigan, USA), DFU
([5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulpho-
nyl)phenyl-2(5H)-furanone]) and L745,337 ((5-meth-
anesulfonamido-6-(2,4-difluorothiophenyl)-1-
indanone)) (both from Merck Frosst, Montreal, Canada).
After the 24 h stimulation period, supernatants were har-
vested for the measurement of the levels of 8-iso-PGF2α
(IUPAC nomenclature: 15-F2t-IsoP), PGD2  (both from
Cayman Chemicals, Ann Arbor, MI, USA), and PGE2
(AssayDesign, distributed by Biotrend, Köln, Germany).
All measurements were performed according to the man-
ufacturer's instructions. The standards were used in the
interval of 3.9-500 pg/ml (detection limit of 5 pg/ml) for
8-iso-PGF2α and 39-2500 pg/ml (sensitivity of the assay
was 36.2 pg/ml) for PGD2 and PGE2.
The same stimulation was used for Western blot analysis
of mPGES-1, COX-1 and COX-2. For mPGES-1, COX-2
and COX-1 immunoblotting, 30 to 50 μg of protein from
each sample was subjected to SDS-PAGE (polyacrylamide
gel electrophoresis) on a 15% gel under reducing condi-
tions. Primary antibodies were goat anti-COX-2 and anti-
COX-1 (M-19 and M-20, respectively, Santa Cruz, Heidel-
berg, Germany) diluted 1:500 in Tris-buffered saline
(TBS) containing 0.1% Tween 20 (Merck, Darmstadt, Ger-
many) and 1% bovine serum albumin (BSA, Sigma), rab-
bit anti-mPGES-1 (Cayman, 1:500), rabbit anti-actin
(Sigma 1:5000).
An AA assay was performed to determine the effect of res-
veratrol on COX-1 and COX-2 enzymatic activity [5]. To
measure total COX activity, SK-N-SH cells were plated in
24-well cell culture plates and pre-incubated with IL-1β
(10 U/ml) for 24 h to induce COX-2 protein synthesis.
After the pre-incubation, medium was replaced by serum-
free medium. Resveratrol was added for 15 min prior to
the addition of AA (15 μM final concentration), which
was supplemented for another 15 min. In control experi-
ments, cells were pre-incubated for 15 min with the fol-
lowing COX inhibitors: SC-58125 (1-[(4-
methysufonyl)phenyl]-3-tri-fluoromethyl-5-(4-fluoroph-
enyl)pyrazole), valeroyl salicylate (VAS) (both com-
pounds obtained from Cayman Chemical Co., Ann Arbor,
Michigan, USA) and SC-560. To measure COX-1 activity,
the procedure was similar, except that no pre-incubation
with IL-1β was performed. Supernatants were collected for
determination of PGE2. The procedure to measure COX
activity by quantification of the PGE2 production by enzy-
matic conversion of AA has been widely used and is well
accepted as a method to evaluate potential COX inhibi-
tors [6-10]. Since AA is exogenously added, this assay is
largely independent of phospholipase activity.
At least three independent experiments were used for data
analysis. All the original data were converted into %-val-
ues of IL-1β control and mean ± S.E.M. were calculated.
IC50 (concentration of the resveratrol that inhibited 50%
of the prostaglandin production) was calculated by com-
puterized non-linear regression analysis. Values were
compared using one-way ANOVA with post-hoc Student-
Newman-Keuls test (multiple comparisons).
Resveratrol did not show toxicity at the doses used as eval-
uated by the ability of the cells to produce ATP (CellTiter-
Glo® luminescent cell viability assay kit, Promega, Man-
nheim, Germany, data not shown).Journal of Neuroinflammation 2009, 6:26 http://www.jneuroinflammation.com/content/6/1/26
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Considering that resveratrol possesses antioxidant activity
[11], we first evaluated whether resveratrol was able to
reduce free radical production in IL-1β-stimulated SK-N-
SH. Isoprostanes are formed from the arachidonate perox-
idation catalysed by free radicals [12] and 8-isoprostanes
are accepted as a reliable and sensitive measure of free rad-
ical formation [13].
IL-1β increased the production of 8-iso-PGF2α, which was
strongly reduced by resveratrol (Fig. 1A), even at very low
concentrations (IC50 = 0.1337 μM), confirming its role as
a natural antioxidant.
We have recently shown that resveratrol inhibits the pro-
duction of PGE2 in LPS-stimulated rat microglia [14]. To
evaluate whether a similar effect occurs in neuronal cells,
we investigated whether resveratrol reduces PGE2 produc-
tion in IL-1β-stimulated SK-N-SH cells. IL-1β (10 U/ml)
strongly induced the production of PGE2 in neuronal
cells. The increased PGE2 production at 24 h was drasti-
cally reduced by resveratrol, even at very low doses (IC50 =
0.05707 μM, Fig. 1B). Moreover, resveratrol also strongly
reduced the production of PGD2 (IC50 = 0.03883 μM, Fig.
1A). To evaluate whether COX inhibitors were able to
reduce the production of PGE2 in the same conditions, we
used COX-1 (SC-560) and COX-2 (L745,337 and DFU)
inhibitors. Interestingly, both the COX-1 and the COX-2
inhibitors reduced the production of PGE2 in IL-1β-stim-
ulated SK-N-SH cells (Fig. 1B), which indicates that COX-
1 activity may also contribute to the production of prosta-
Resveratrol dose-dependently inhibited IL-1β-induced production of 8-iso-PGF2α, PGD2 (A) and PGE2 (B) in SK-N-SH cells Figure 1
Resveratrol dose-dependently inhibited IL-1β-induced production of 8-iso-PGF2α, PGD2 (A) and PGE2 (B) in SK-
N-SH cells. Selective inhibitors of COX-2 (L745,337 and DFU) and COX-1 (SC-560) were included as controls (B). Cells 
were incubated with the compounds for 30 minutes and subsequently treated with IL-1β (10 U/ml) for 24 h. Data are 
expressed as mean ± S.E.M. of at least 3 independent experiments.
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noids in stimulated cells. Because this experimental set up
did not clarify the mechanism of inhibition of the produc-
tion of prostanoids by resveratrol, we performed further
experiments to investigate this issue.
Since PGE2 is produced mainly by COX-2 and mPGES-1
in stimulated cells, we investigated whether the inhibitory
effect of resveratrol on PGE2 was due to regulation of the
synthesis of these two enzymes. IL-1β increased the pro-
tein synthesis of mPGES-1 and COX-2 (Fig. 2A and 2B).
Resveratrol, at doses that significantly inhibited PGE2 pro-
duction, did not significantly reduce mPGES-1 and COX-
2 immunoreactivities (Fig. 2A and 2B). In addition, COX-
1 protein also remained unaffected (Fig. 2A).
A and B: Immunoblot analysis of the protein levels of mPGES-1, COX-2 and COX-1 in IL-1β-stimulated SK-N-SH cells treated  with resveratrol Figure 2
A and B: Immunoblot analysis of the protein levels of mPGES-1, COX-2 and COX-1 in IL-1β-stimulated SK-N-
SH cells treated with resveratrol. Resveratrol does not inhibit IL-1β-induced levels of mPGES-1, COX-2 in SK-N-SH cells. 
Cells were incubated with resveratrol for 30 minutes and subsequently treated with IL-1β (10 U/ml) for 24 h. Data are 
expressed as mean ± S.E.M. of at least 3 independent experiments.Journal of Neuroinflammation 2009, 6:26 http://www.jneuroinflammation.com/content/6/1/26
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To further clarify the mechanisms responsible for the
reduction of PGE2 and PGD2, we investigated whether res-
veratrol reduces COX activity. Although resveratrol is a
well-known COX-1 inhibitor, it did not inhibit the COX-
1 activity at the same doses that reduced PGE2 production
in SK-N-SH cells (Fig. 3A). A similar effect was obtained
with SC-58125 (COX-2 inhibitor), which did not reduce
the PGE2 production in this assay (Fig. 3B). On the other
hand, SC-560 and VAS (COX-1 inhibitors), strongly
reduced PGE2 formation (Fig. 3B).
Although low concentrations of resveratrol did not inhibit
COX-1 activity (Fig. 3A), it significantly reduced total
COX activity even at low doses (0.01-5 μM) as shown in
an assay used to test both COX-1 and COX-2 activities
(Fig. 3C). A strong reduction of PGE2 was also observed
with SC-58125, a COX-2 inhibitor. However, only a par-
tial reduction in PGE2 content was observed with a high
concentration of SC-560 (10 μM) and no reduction was
observed with VAS, both COX-1 inhibitors (Fig. 3D), con-
firming our previous results [15]. It is known that the IC50
values for SC-560 are 9 nM and 6.3 μM for COX-1 and
COX-2, respectively [16]. Therefore, although COX-1
might play a role in this assay, it is possible that at the
higher concentration (10 μM), SC-560 also partially
inhibits PGE2 production by interfering with COX-2 activ-
ity. Since at low doses resveratrol did not reduce COX-1
activity (Fig. 3A), inhibition of COX-2 might account for
the significant reduction of total COX activity seen at low
doses of resveratrol (Fig. 3B).
In the present study, we show that resveratrol, a flavonoid
present in some plants and in the red wine, reduced pros-
tanoid synthesis and free radical generation without
Effect of resveratrol on COX-1 (A) and total COX (C) activity in SK-N-SH cells Figure 3
Effect of resveratrol on COX-1 (A) and total COX (C) activity in SK-N-SH cells. The arachidonic acid assay was 
performed as described in the text. Selective inhibitors of COX-1 (SC-560 and VAS) and COX-2 (SC-58125) were included in 
the COX-1 (B) and total COX (D) activity assays to assess the relative contribution of each isozyme to the overall COX enzy-
matic activity. Data are expressed as mean ± S.E.M. of at least 3 independent experiments. *p < 0.05, **p < 0.01 and ***p < 
0.001 with respect to IL-1β control (One-way ANOVA followed by the Student-Newman-Keuls post-hoc test).
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affecting the expression of COX-2 and mPGES-1 in neuro-
nal cells. This effect may be attributed to the inhibition of
COX activity, mainly COX-2, and antioxidant properties.
The search for compounds that have a potential to reduce
neuroinflammation has increased exponentially. Resvera-
trol is in focus for this purpose, because of its plethora of
pharmacological effects and since there are evidences sug-
gesting that its metabolites can cross the blood-brain bar-
rier [17-20], although this availability might not be
achieved by a dietary administration [21].
The pharmacological properties of resveratrol are of a
great interest, since it goes beyond its antioxidant proper-
ties. Resveratrol has been shown to reduce the synthesis of
iNOS [22] and cytokines [23-25] in different cells. How-
ever, just a few papers showed the direct effects of resver-
atrol on neuronal cells [26-29]. SK-N-SH cells, because of
their similarity with primary neuronal cells, are a useful
cellular model for studying neuropathological processes
that might play a role in neurodegenerative disorders.
Here we demonstrated that resveratrol strongly reduced
prostaglandin synthesis without affecting COX-2 and
mPGES-1 expression. Recently, using six different human
uterine cell lines, Sexton et al. [30] showed that resvera-
trol, although having opposite effects on COX-2 expres-
sion depending on the cell line, reduced PGE2 in almost
all cell types tested. On the other hand, resveratrol
reduced COX-2 promoter activity and expression and
PGE2 production in different cells [31-34]. We also have
recently demonstrated that resveratrol reduces mPGES-1
expression, PGE2  and 8-iso-PGF2α  generation, without
interfering with COX-2 expression in LPS-stimulated
microglia [14]. Therefore, the effect of resveratrol on
COX-2 and mPGES-1 expression might be dependent on
the cell type.
Similar to our results, resveratrol has been shown to
inhibit PGD2 production induced by IgE in bone marrow-
derived mouse mast cells in vitro [35] and PGD2 and
COX-2 expression in the colon in a rat model of chronic
colitis [36].
Although resveratrol is known as a COX-1 inhibitor, it did
not reduce COX-1 activity at the doses that PGE2 and
PGD2 content were reduced. However, COX-2 activity was
reduced even at low concentrations that might be impor-
tant to the reduction of the prostanoids. Other studies
have also demonstrated that resveratrol is able to reduce
COX-2 activity [14,33,37,38]. Although in our experimen-
tal set up resveratrol reduced PG formation in the AA assay
probably by inhibiting COX-2 activity, it is possible that it
reduced the activity of other PGE synthases, such as
mPGES-1, even considering that the experimental condi-
tions used were not appropriated to measure mPGES-1
activity, which demands glutathione and other reagents
[39-41]. Moreover, a reduction in the phospholipase A2
activity and AA release might also contribute to the reduc-
tion in the prostanoid formation [42].
Resveratrol also diminished isoprostane formation in IL-
1β-stimulated SK-N-SH cells. This ability can be explained
by its antioxidant activity and by the reduction of COX-2
activity induced by resveratrol. We and others have dem-
onstrated that 8-iso-PGF2α formation can also be depend-
ent on COX-2 activity [13,15,43].
Recently, Jin et al. [44] demonstrated that chronic per os
administration of resveratrol significantly improved the
neurobehavioral deficit and reduced the expression of
COX-2 in the substantia nigra in rats administered with 6-
hydroxydopamine, a substance used to simulate an ani-
mal model of Parkinson's disease. Since the COX-2 levels
were measured in a brain region, it is not possible to
establish its major cellular source, which could be neu-
rons or glial cells. Resveratrol also reduced the apoptotic
dopaminergic neuronal death induced by microglia acti-
vation in a microglial-neuronal coculture [29]. The neuro-
protection conferred by resveratrol might be related to the
ability to reduce the production of prostaglandins and
free radicals in neurons and microglia.
In summary, we conclude that resveratrol reduced the
prostaglandin formation in neuronal cells probably by
inhibiting the activity of inducible PG synthesizing
enzymes, such as COX-2, but with a weak influence on
COX-1 activity and not interfering with the expression of
COX-1, COX-2 or mPGES-1. These effects further support
the interest of resveratrol as a potential tool in the treat-
ment of neuroinflammatory conditions.
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